INTRODUCTION
Major Depressive Disorder (MDD) is a highly prevalent condition that has been labeled the current leading cause of disability adjusted life years (Ferrari et al. 2013 ). Approximately 30% of MDD patients are treatment resistant, not achieving remission after two or more antidepressant trials (Baldessarini et al. 2015) . In the geriatric population, MDD is associated with both lower rates of remission and increased levels of recurrence (Kiosses & Alexopoulos 2013 ). Geriatric MDD not only shows an impoverished response to pharmacological approaches, but also presents new treatment challenges associated with clinical limitations such as frequent metabolic issues, comorbidity and poly-medication. Hence, additional therapeutic alternatives such as repetitive transcranial magnetic stimulation (rTMS) might be beneficial in these resistant cases (Downar & Daskalakis 2013) .
Currently, the left dorsolateral prefrontal cortex (DLPFC) is the stimulation target recommended by the Food and Drug Administration when treating MDD (Lefaucheur et al. 2014 ). However, evidence from patients with brain lesions, functional neuroimaging, and neuromodulation studies, suggests that there are other potential rTMS targets to promote MDD remission, such as the dorsomedial prefrontal cortex (Downar & Daskalakis 2013, Lefaucheur et al. 2014 ). This case report aims to describe the clinical remission experienced by an elderly patient with treatment resistant MDD after a 20 session course of bilateral 10 Hz DMPFC-rTMS.
CASE REPORT
The patient described in this case report provided written informed consent to engage in this study. Furthermore, the study was approved by the ethics committee of the Institute of Psychiatry -Federal University of Rio de Janeiro (protocol CAEE 2319813.0.0000.526). The patient is a 60 year-old, retired Caucasian male, referred to the Institute of Psychiatry (IPUB-UFRJ), and who presented a current severe episode of MDD without psychotic symptoms by DSM-5 criteria. The patient had a 38-year long history of treatment-resistant MDD, during which he underwent several pharmacological interventions and psychotherapy, always with unsustained partial responses. Depressive symptoms had been escalating for the last 3 years without response to multiple courses of antidepressants (fluoxetine 60mg/day, paroxetine 60mg/day, nortriptyline 50mg/day, bupropion 300mg/day) with posteriorly adjuvant treatment (olanzapine 10mg/day, lithium 900mg/day, Haldol 5mg/day and valproate 1000mg/day).
During examination, he maintained a curved posture and complained of fatigue, anhedonia and sadness. He recurrently spoke about anxiety, feelings of despair, ruminative thoughts about dying, and feelings of severe guilt associated with life occurrences. In addition, he reported having changes in appetite and difficulties with sleep regulation, associated with a complete lack of motivation to perform daily activities or self-care. The patient had no signs or symptoms suggestive of retrospective mania, dysthymic or personality disorder. Mini Mental State Examination (MMSE) scored 27/30, and executive function clinical tests (clock test and verbal fluency test) showed no signs of cognitive impairment. The patients' most frequent complaint was a "feeling of mental laziness", impaired reasoning, and difficulties recalling names, dates and autobiographical events. Neurological and laboratory investigation showed no abnormalities.
After explaining available treatment options to the patient, rTMS was chosen. The patient completed a clinical scale to measure depression severity (Hamilton Depression Rating Scale -HAMD-17) and a self-report questionnaire to assess anxiety symptoms (State-Trait Anxiety Inventory -STAI-T/S) at baseline, after intervention (4-week) and at follow-up (5-months).
The patient was instructed to maintain his current medication scheme (clomipramine 150mg/day, mirtazapine 45mg/day, quetiapine 50mg/day, lorazepam 3mg/day) during the intervention. The rTMS protocol administered consisted of 10 Hz stimulation at 120% of the resting motor threshold for 30 min (2880 pulses per session), 5 times per week consecutively for 4 weeks, over the bilateral DMPFC (Fz electrode site in the 10/20 International EEG system), without neuronavigation, using the fluid-cooled AFEC-02-100 figure 8 At baseline the patient had very severe depression (HAMD-17 =33) and severe trait and state anxiety (STAI-T/S =66/70). After 4 weeks, the patient effectively responded to the treatment (≥50% depressive symptoms reduction), although he still presented some mild depressive symptoms (HAMD-17 =13) and anxiety (STAI-T/S =33/31). The patient also reported a marked improvement in his memory, attention and executive function, although these findings were not confirmed with formal neuropsychological testing. Local discomfort and headache were the only reported side effects after rTMS and were managed with paracetamol. After 5 months the patient displayed full and sustained remission (HAMD-17 =4), moderate trait and mild state anxiety (STAI-T/S =40/27). As of 18 months since finishing the procedure, he has not displayed any MDD recurrence.
CONCLUSIONS
To our knowledge this is the first case of treatment resistant geriatric MDD in the literature which showed full remission after a course of bilateral DMPFC-rTMS. There are two important topics highlighted in this case report. First, our findings suggest that when it comes to the geriatric population, which commonly has several contraindications for specific pharmacological agents (Alexopoulos et al. 1996), rTMS may represent a therapeutic alternative to increase the number of treatment responders while maintaining safety and tolerability. Previous evidence from 7912 DMPFC-rTMS runs found no seizures or other serious adverse effects after stimulation suggesting its safety and tolerance for medication-resistant major depressive disorder (Bakker et al. 2015) .
A recent trial also analyzed the cognitive safety profile of DMPFC-rTMS on treatment resistant depressive patients and did not found any performance hindering on learning, attention, speed of processing and cognitive flexibility measures (Schulze et al. 2016 ). Conversely, there were actually significant improvements with large effects on cognitive flexibility measures. In our case report there were no significant adverse effects of DMPFC-rTMS other than local discomfort and headache, with the patients actually reporting subjective improvement in cognitive performance.
Second, this case allows us to debate if DMPFCrTMS produces sustained and improved outcomes when compared to DLPFC-rTMS in cases of geriatric MDD. However, resting-state functional MRI evidence has highlighted the DMPFC as a "dorsal nexus" in depression, suggesting its role as a distinctive brain region that promotes increased connectivity between the cortical networks for cognitive control, affect regulation and selfreflection (Sheline et al. 2010 ). Furthermore, a recent retrospective case series with 185 adult patients with medication-resistant MDD analyzed the effectiveness of 10 Hz and theta burst DMPFC-rTMS stimulation protocols (Bakker et al. 2015) . Combined data from both procedures showed similar effects in comparison to DLPFCrTMS on overall response and remission rates in clinician-rated and self-reported measures. There is also preliminary evidence showing how can resting-state functional connectivity predict treatment response to DMPFCrTMS, with higher cortical-cortical connectivity and lower cortico-thalamic, cortico-striatal, and cortico-limbic connectivity seeming to be associated to better treatment outcomes , Downar et al. 2014 .
Thereby, excitatory rTMS may provide enhanced emotional self-regulation and impulse control, leading to depressive symptoms amelioration. Although just emerging as a treatment for geriatric MDD, this case suggests that rTMS of the DMPFC is worth further investigation as a therapeutic intervention. Coil placement is simpler at the DMPFC and can be accurately achieved even without MRI guidance, making it a strong candidate for widespread use in MDD management (Downar & Daskalakis 2013 ). Although our case-report showed sustained remission for 18 months without additional stimulation sessions, future studies should explore whether and when geriatric patients should receive additional DMPFCrTMS sessions during the maintenance phase. Randomized sham-controlled trials to assess the efficacy of DMPFC-rTMS in geriatric MDD are also welcomed and they could drastically improve our ability to treat these patients safely and effectively.
